Recent research has put a spotlight on a number of factors which could be used to estimate which patients with nonmetastatic, unfavorable-risk prostate cancer are at high risk for a shorter time until ...

Researchers determined that the Huber et al. criteria regarding prostate-specific antigen (PSA) levels may more accurately predict the need for additional treatment or the possibility of treatment ...

For the hundreds of thousands of men who undergo radical prostatectomy each year, one question looms over every postoperative ...

Prostate cancer is the most common cancer among men in South Korea, and even after surgical removal of the prostate, one in ...

A case report led by UCLA Health researchers highlights the importance of a multidisciplinary, evidence-based approach to ...

Treatments intended to reduce biochemical recurrence in patients with prostate cancer may not improve long-term survival, recent research showed. Certain prostate cancer treatments used to reduce the ...

Biochemical recurrence is when your PSA level starts to rise after finishing prostate cancer treatment, and it may sometimes indicate metastatic disease. Biochemical recurrence is a term for when your ...

SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...

− Post-hoc analysis from Blue Earth Diagnostics’ Phase 3 SPOTLIGHT trial provides data about treatment planning, particularly when curative salvage therapy is considered – MONROE TOWNSHIP, N.J. & ...

A previous Point-of-Care Guide 1 identified a clinical decision rule that estimates the likelihood of an abnormal biopsy for prostate cancer. One of the next questions facing the patient and his ...